Although no previous data on the use of eslicarbazepine acetate during lactation are available, limited but reassuring data have been reported with oxcarbazepine, of which eslicarbazepine is a major metabolite. Given the well-known benefits of breastfeeding, and according to the above reassuring data, breastfeeding under clinical supervision could be considered for healthy full-term infants of mothers on eslicarbazepine acetate monotherapy. However, parents should be warned that data concerning the safety of eslicarbazepine during breastfeeding are scarce, and long-term neurodevelopment outcomes in breastfed children are unknown. Additionally, the infants' serum levels should be measured in case of an unexplained adverse reaction.
Thais et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: